Thermo Fisher Scientific (TMO) Receives Consensus Recommendation of “Buy” from Analysts

Thermo Fisher Scientific (NYSE:TMO) has been assigned an average recommendation of “Buy” from the eighteen research firms that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $220.08.

Several equities research analysts recently commented on the stock. Morgan Stanley reduced their price target on shares of Thermo Fisher Scientific from $228.00 to $216.00 and set an “overweight” rating for the company in a research report on Wednesday, April 11th. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $228.00 price target for the company in a research report on Tuesday, April 3rd. Leerink Swann restated an “outperform” rating and issued a $239.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Thursday, February 1st. They noted that the move was a valuation call. Barclays upped their price target on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Finally, ValuEngine upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd.

How to Become a New Pot Stock Millionaire

In other news, SVP Gregory J. Herrema sold 33,327 shares of the stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the transaction, the senior vice president now owns 60,471 shares in the company, valued at approximately $13,285,478.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 40,000 shares of the stock in a transaction on Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the transaction, the chief executive officer now owns 334,622 shares in the company, valued at approximately $70,324,159.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 88,827 shares of company stock worth $19,012,672. Company insiders own 0.49% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Icon Wealth Partners LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $105,000. Bank of Nova Scotia Trust Co. acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth $106,000. Keeler Thomas Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $106,000. Virtue Capital Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $127,000. Finally, Premia Global Advisors LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $131,000. Institutional investors own 87.62% of the company’s stock.

Shares of NYSE:TMO opened at $219.53 on Thursday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.34 and a quick ratio of 0.92. The company has a market capitalization of $86,749.20, a P/E ratio of 23.13, a PEG ratio of 1.59 and a beta of 1.15. Thermo Fisher Scientific has a 52 week low of $152.92 and a 52 week high of $226.44.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.66 by $0.13. The business had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $5.72 billion. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The firm’s quarterly revenue was up 22.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.41 EPS. research analysts expect that Thermo Fisher Scientific will post 10.84 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 16th. Shareholders of record on Thursday, March 15th were paid a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.31%. The ex-dividend date of this dividend was Wednesday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio is currently 7.17%.

TRADEMARK VIOLATION WARNING: “Thermo Fisher Scientific (TMO) Receives Consensus Recommendation of “Buy” from Analysts” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/19/thermo-fisher-scientific-tmo-receives-consensus-recommendation-of-buy-from-analysts.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply